Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Improved CRISPR-based bacterial sepsis test with better stability, activity, and wider target range

Updated

Abstract

Essence

A MOF-encapsulated PAM-relaxed CRISPR-Cas12a platform showed broad and stable detection of sepsis-causing bacteria.

Evidence

Diagnostic platform and formulation study tested CRISPR-FLEXMO in bacterial lysates, stressed storage conditions, and serum samples from 15 sepsis patients and 3 healthy individuals.

Caveat

The reported 100% serum sensitivity and specificity come from only 18 human samples, so clinical diagnostic performance remains uncertain.

Simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free